Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study
暂无分享,去创建一个
C. Berking | M. Neurath | R. Atreya | A. Liphardt | G. Schett | M. Sticherling | K. Tascilar | M. Leppkes | A. Kleyer | D. Simon | L. Schuster | P. Dietrich | S. Kleinert | A. Hueber | G. Krönke | B. Manger | A. Ramming | J. Knitza | V. Schönau | F. Fagni | F. Schuch | T. Orlemann | M. Pachowsky | K. Manger | M. Ronneberger | F. Hartmann | C. Meder | J. Taubmann | I. Minopoulou | J. Mößner | M. Y. Mutlu | S. Kemenes | D. Bohr
[1] A. Fomsgaard,et al. Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine , 2022, JAMA network open.
[2] M. Mulligan,et al. Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease , 2022, The Lancet Rheumatology.
[3] G. Kaplan,et al. Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis , 2022, The Lancet Rheumatology.
[4] S. Nejentsev,et al. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies , 2022, The Lancet Rheumatology.
[5] R. R. Hagen,et al. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study , 2022, The Lancet Rheumatology.
[6] A. Iagnocco,et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update , 2022, Annals of the Rheumatic Diseases.
[7] D. Segev,et al. Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease , 2022, The Lancet Rheumatology.
[8] C. Berking,et al. Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS–CoV‐2 in an Unvaccinated Cohort , 2021, Arthritis & rheumatology.
[9] T. Harrer,et al. Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease , 2021, Annals of the Rheumatic Diseases.
[10] Lindsay N. Carpp,et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial , 2021, Science.
[11] Gregory F. Wu,et al. Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-α inhibitors , 2021, Med.
[12] C. Hirzel,et al. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study , 2021, The Lancet Rheumatology.
[13] Gregory F. Wu,et al. Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 , 2021, Annals of Internal Medicine.
[14] J. Mascola,et al. Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants , 2021, Science.
[15] J. Sparks,et al. Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases , 2021, Annals of the Rheumatic Diseases.
[16] M. Boers,et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies , 2021, The Lancet Rheumatology.
[17] M. Neurath,et al. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses , 2021, The Lancet Rheumatology.
[18] J. Vekemans,et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[19] Mimi Y. Kim,et al. Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort , 2021, The Lancet Rheumatology.
[20] M. Neurath,et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease , 2021, Annals of the Rheumatic Diseases.
[21] D. Segev,et al. High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases , 2021, Annals of the Rheumatic Diseases.
[22] M. Neurath,et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease , 2021, Annals of the Rheumatic Diseases.
[23] C. Berking,et al. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases , 2021, Annals of the Rheumatic Diseases.
[24] P. Hoff,et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort , 2021, Annals of the Rheumatic Diseases.
[25] J. Sparks,et al. SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease , 2021, Annals of the Rheumatic Diseases.
[26] A. Ogdie,et al. COVID‐19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease‐Modifying Antirheumatic Drugs on Clinical Outcomes , 2020, Arthritis & rheumatology.
[27] C. Berking,et al. Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion , 2020, Nature Communications.
[28] A. Neimann,et al. Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York , 2020, The New England journal of medicine.